CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 219 enrolled
Drug / intervention
Buprenorphine +1 moredrug
Likely dose
Buprenorphine 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00324038
NCT00324038Phase 4Completed
CompareCT.gov

An Open, Randomised, Multicentre Study to Compare Buprenorphine Transdermal Delivery System (BTDS) With Standard Treatment in Elderly Subjects With OA of the Hip and/or Knee

Napp Pharmaceuticals Limited·interventional·Posted May 10, 2006·Updated Jun 14, 2011

In Brief

A Phase 4 clinical trial evaluating Buprenorphine and Codeine paracetamol for Osteoarthritis. Completed, enrolled 219 participants across 1 site.

Detailed Summary

The primary objective is to compare buprenorphine transdermal delivery system (BTDS) with standard- treatment in subjects with osteoarthritis (OA).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 10, 2006
Enrollment StartMar 1, 2006
Study CompletionDec 1, 2007
TodayJul 2, 2026
Posted 20.1 years ago

Interventions

Buprenorphinedrug

buprenorphine transdermal system 5, 10 and 20 mg

Codeine paracetamoldrug

combination tablet of codeine and paracetamol taken orally 3 or 4 times daily. Dosage form ranges from 8/500, 15/500 and 30/500